Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;11(11):1673.
doi: 10.3390/vaccines11111673.

Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium"

Maarten J Postma  1   2 , Chih-Yuan Cheng  3 , Nasuh C Buyukkaramikli  3 , Luis Hernandez Pastor  3 , Ine Vandersmissen  4 , Thierry Van Effelterre  3 , Peter Openshaw  5 , Steven Simoens  6
Affiliations

Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium"

Maarten J Postma et al. Vaccines (Basel). .

Abstract

We have read the commentary from Baudouin Standaert [...].

PubMed Disclaimer

Conflict of interest statement

M.J.P. holds stocks in Health-Ecore (Zeist, Netherlands) and PAG BV (Groningen, Netherlands). C.-Y.C., N.C.B., L.H.P., I.V. and T.V.E. are employees of Janssen Pharmaceuticals and may hold shares of Johnson & Johnson. T.V.E. also declares holding shares of GSK. P.O. has been a member of scientific advisory panels for GSK, Moderna, Janssen, Seqirus and Pfizer. S.S. has been involved in research on the value of vaccines funded by GSK, MSD, and Pfizer.

References

    1. Standaert B. Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 2023, 11, 990. Vaccines. 2023;11:1646. doi: 10.3390/vaccines11111646. - DOI - PMC - PubMed
    1. Postma M.J., Cheng C.-Y., Buyukkaramikli N.C., Hernandez Pastor L., Vandersmissen I., Van Effelterre T., Openshaw P., Simoens S. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines. 2023;11:990. doi: 10.3390/vaccines11050990. - DOI - PMC - PubMed
    1. Bergeron H.C., Tripp R.A. Immunopathology of RSV: An Updated Review. Viruses. 2021;13:2478. doi: 10.3390/v13122478. - DOI - PMC - PubMed
    1. Belongia E.A., King J.P., Kieke B.A., Pluta J., Al-Hilli A., Meece J.K., Shinde V. Clinical Features, Severity, and Incidence of RSV Illness during 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old. Open Forum Infect. Dis. 2018;5:ofy316. doi: 10.1093/ofid/ofy316. - DOI - PMC - PubMed
    1. Ackerson B., Tseng H.F., Sy L.S., Solano Z., Slezak J., Luo Y., Fischetti C.A., Shinde V. Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus versus Influenza Infection in Hospitalized Older Adults. Clin. Infect. Dis. 2019;69:197–203. doi: 10.1093/cid/ciy991. - DOI - PMC - PubMed

LinkOut - more resources